GlassScriptPhysician profile
Aman Nasir
NPI 1265728406
$5,125.59
in general payments reported to CMS, 2019-2025
28 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2022: $42.12 · 2023: $529 · 2024: $2,175 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,715 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,714.61 |
| Education | $145.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,091.13 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $704.97 | 2023-2025 | Dupixent |
| Genzyme Corporation | $555.33 | 2023-2025 | |
| Glaxosmithkline, LLC. | $526.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Pfizer INC. | $281.67 | 2019-2025 | |
| Amgen INC. | $264.74 | 2023-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $204.01 | 2024-2025 | |
| Csl Behring | $167.07 | 2025 | Hizentra, Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $154.47 | 2023-2025 | Cuvitru, Takhzyro |
| Pharming Healthcare, INC. | $133.45 | 2024-2025 | Ruconest |
| Genentech USA, INC. | $113.67 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $88.99 | 2025 | |
| Optinose US, INC. | $86.88 | 2019-2025 | |
| Kaleo, INC. | $85.05 | 2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $83.59 | 2025 | Orladeyo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $68.41 | 2025 | Neffy |
| Lilly USA, LLC | $58.12 | 2024-2025 | Ebglyss |
| Incyte Corporation | $56.82 | 2024-2025 | Opzelura |
| Abbvie INC. | $55.18 | 2024 | |
| Alk-Abello, INC | $51.00 | 2025 | Standardized Mite D. Farinae, Timothy, Standardized, Pre-Pen |
| Grifols USA, LLC | $50.49 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Organon LLC | $48.31 | 2025 | Vtama |
| Hikma Pharmaceuticals USA | $44.03 | 2024-2025 | Ryaltris |
| Qol Medical, LLC | $42.12 | 2022 | |
| Ionis Pharmaceuticals, INC. | $38.75 | 2025 | Dawnzera |
| Greer Laboratories, INC. | $28.05 | 2024 | Palforzia |
| Blueprint Medicines Corporation | $26.29 | 2023 | Ayvakit |
| Galderma Laboratories, L.P. | $16.40 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.